Cargando…

Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP

The human T-cell lymphotropic virus type 1 (HTLV-1) is the known causative agent of a chronic neurologic condition known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although several therapies have been evaluated for HAM/TSP, none have been approved for use in humans. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Davi Tanajura, Sundberg, Michael, Passos, Lúcia, Muniz, André Luiz, Santos, Silvane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431060/
https://www.ncbi.nlm.nih.gov/pubmed/22953092
http://dx.doi.org/10.1155/2012/958786
_version_ 1782242021047533568
author Costa, Davi Tanajura
Sundberg, Michael
Passos, Lúcia
Muniz, André Luiz
Santos, Silvane
author_facet Costa, Davi Tanajura
Sundberg, Michael
Passos, Lúcia
Muniz, André Luiz
Santos, Silvane
author_sort Costa, Davi Tanajura
collection PubMed
description The human T-cell lymphotropic virus type 1 (HTLV-1) is the known causative agent of a chronic neurologic condition known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although several therapies have been evaluated for HAM/TSP, none have been approved for use in humans. In this paper, we describe a 55-year-old female patient with HAM/TSP who was treated with interferon beta-1a. This patient, in comparison to 20 female patients with HAM/TSP who were not treated, showed improvement in urinary symptoms over four years of therapy, as well as a reduction in HTLV-1 proviral load and serum cytokine levels typically observed in HAM/TSP. This improved outcome merits further controlled studies on the use and efficacy of interferon beta-1a as a therapy for HAM/TSP.
format Online
Article
Text
id pubmed-3431060
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-34310602012-09-05 Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP Costa, Davi Tanajura Sundberg, Michael Passos, Lúcia Muniz, André Luiz Santos, Silvane Case Rep Neurol Med Case Report The human T-cell lymphotropic virus type 1 (HTLV-1) is the known causative agent of a chronic neurologic condition known as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Although several therapies have been evaluated for HAM/TSP, none have been approved for use in humans. In this paper, we describe a 55-year-old female patient with HAM/TSP who was treated with interferon beta-1a. This patient, in comparison to 20 female patients with HAM/TSP who were not treated, showed improvement in urinary symptoms over four years of therapy, as well as a reduction in HTLV-1 proviral load and serum cytokine levels typically observed in HAM/TSP. This improved outcome merits further controlled studies on the use and efficacy of interferon beta-1a as a therapy for HAM/TSP. Hindawi Publishing Corporation 2012 2012-08-16 /pmc/articles/PMC3431060/ /pubmed/22953092 http://dx.doi.org/10.1155/2012/958786 Text en Copyright © 2012 Davi Tanajura Costa et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Costa, Davi Tanajura
Sundberg, Michael
Passos, Lúcia
Muniz, André Luiz
Santos, Silvane
Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP
title Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP
title_full Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP
title_fullStr Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP
title_full_unstemmed Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP
title_short Interferon Beta-1a Improves Urinary Symptoms, Reduces Proviral Load, and Modifies the Immune Response in a Patient with HAM/TSP
title_sort interferon beta-1a improves urinary symptoms, reduces proviral load, and modifies the immune response in a patient with ham/tsp
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3431060/
https://www.ncbi.nlm.nih.gov/pubmed/22953092
http://dx.doi.org/10.1155/2012/958786
work_keys_str_mv AT costadavitanajura interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp
AT sundbergmichael interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp
AT passoslucia interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp
AT munizandreluiz interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp
AT santossilvane interferonbeta1aimprovesurinarysymptomsreducesproviralloadandmodifiestheimmuneresponseinapatientwithhamtsp